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Depression is among the leading causes of disability worldwide1
which in its severe forms can be life threatening. Severely depressed
patients, or those who fail to respond to chemical treatment, are
commonly treated with electroconvulsive therapy (ECT). ECT is
highly effective and undoubtedly saves lives, but a range of factors,
including side-effect profile, the necessity for hospital care and
stigma, restricts its use.2 Mitigating these factors may improve
the acceptability of ECT as a treatment. Ketamine is a candidate
mitigation agent because of renewed interest in it as an acute
treatment for severe depression3–6 and as an anaesthetic during
ECT (see for example McGirr et al,6,7 Caddy et al,8 Fond et al,9
Coyle & Laws,10 and Lee et al11). McGirr et al7 pooled the
results of many anaesthetic and adjunct ketamine studies and
concluded that ketamine anaesthesia in ECT leads to a
therapeutic improvement. Unfortunately, many variations in
methodology including in electrode placement, seizure threshold,
limiting the number of treatments and depression rating scales
used, limit the generalisability of the conclusions that can be
drawn from the work published to date. A recent Cochrane
review8 concluded that higher-quality randomised controlled
trials (RCTs) investigating ketamine as a treatment for depression
were needed. Ketamine anaesthesia during ECT may also have
additional or independent neuroprotective effects against deficits
in cognitive function associated with ECT.12,13 Ketamine is
a non-competitive N-methyl-D-aspartate (NMDA) receptor
antagonist and activation of NMDA receptors is required for the
induction of a form of synaptic plasticity called long-term
potentiation (LTP),14 a potential mechanism underlying memory
formation.15 Previous studies in rodents have shown that the use
of ketamine anaesthesia during electroconvulsive stimulation can
prevent LTP-like changes in the hippocampus.16 Consistent with
the cognition-sparing hypothesis is the evidence that using
ketamine as the anaesthetic in patients receiving ECT resulted in
faster re-orientation time compared with methohexital,17 and
also protected word recall after six treatments compared with
etomidate.18
Here we present the results of the KANECT trial (‘The use of
ketamine as an anaesthetic during electroconvulsive therapy
(ECT) for depression: does it improve treatment outcome?’,
trial registration: European Clinical Trials Database (EudraCT):
2011-000396-14 and clinicalTrials.gov: NCT01306760.). KANECT
was a double-blind, parallel-design, RCT of ketamine with an
active comparator, propofol (used in 88.2% of ECT treatments
in Scotland19), as the anaesthetic for ECTwith follow-up intervals
during, immediately after and 1 month after ECT. The primary
objective was to determine if using ketamine instead of propofol
resulted in fewer ECT treatments and quicker improvements in
ratings of depression severity. The secondary objective was to
determine if using ketamine resulted in less cognitive impairment
following ECT.
Method
Trial design
KANECT was a double-blind, parallel-design, randomised
controlled trial of ketamine with an active comparator, prpofol,
as the anaesthetic for ECT. Once consent had been obtained
baseline assessments were made before patients were randomised
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Background
Ketamine has recently become an agent of interest as an
acute treatment for severe depression and as the anaesthetic
for electroconvulsive therapy (ECT). Subanaesthetic doses
result in an acute reduction in depression severity while
evidence is equivocal for this antidepressant effect with
anaesthetic or adjuvant doses. Recent systematic reviews
call for high-quality evidence from further randomised
controlled trials (RCTs).
Aims
To establish if ketamine as the anaesthetic for ECT results in
fewer ECT treatments, improvements in depression severity
ratings and less memory impairment than the standard
anaesthetic.
Method
Double-blind, parallel-design, RCT of intravenous ketamine
(up to 2mg/kg) with an active comparator, intravenous
propofol (up to 2.5mg/kg), as the anaesthetic for ECT in
patients receiving ECT for major depression on an informal
basis. (Trial registration: European Clinical Trials Database
(EudraCT): 2011-000396-14 and clinicalTrials.gov: NCT01306760.)
Results
No significant differences were found on any outcome
measure during, at the end of or 1 month following the
ECT course.
Conclusions
Ketamine as an anaesthetic does not enhance the efficacy of
ECT.
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to one of the two anaesthetics using minimisation. The
minimisation variables were gender and age. No random element
was employed so Taves’20 method with P= 1 was used. Treatment
allocation was 1:1 ketamine:propofol. Randomisation was
performed over the internet or telephone using an independent
randomisation service (CHaRT, University of Aberdeen) by the
principal investigator (I.C.R.) or ECT nurses and recorded in
medical notes as drug A or B. An unblinding procedure was
specified should the medical need arise. All post-ECT assessments
were conducted by researchers masked to the anaesthetic assignment.
Recruited patients received ECT as per the routine processes at
the Royal Cornhill Hospital until their consultant psychiatrist
(masked to anaesthetic assignment) decided to end treatment or
treatment was stopped for medical reasons. KANECT was given
ethical approval by the East of Scotland Research Ethics Service
(ref: 11/AL/0221) and approved by the Medicine and Healthcare
products Regulatory Agency (ref: 21583/0211/001-0001).
Participants
Patients were eligible to participate if they were: receiving ECT on
an informal basis (i.e. not detained), considered fit by an
anaesthetist (American Society of Anaesthesiologists physical
status classification system score of 1 or 2), had no comorbid
psychiatric diagnoses recorded by the treating psychiatrist and
were between the ages of 18 and 75. Patients were excluded if they
had pre-existing neurological disease or cognitive impairment,
pre-existing severe hypertension, severe respiratory tract
disease, major cardiovascular disease, a pacemaker, significant
cerebrovascular disorder or malformation, intracranial mass
lesions, seizure disorder, intracranial electrode and clips, severe
intra-ocular pathology, significant endocrine or metabolic disease,
severe haematological disease, severe fracture, obesity, pregnancy.
Patients were receiving ECT for major depression on an informal
basis at the Royal Cornhill Hospital, Aberdeen, Scotland between
November 2011 and December 2013. The final assessment of the
final patient was completed in February 2014. The ethnicity of
all patients was White British. All participants provided informed
consent.
Interventions
Ketamine (Ketalar, manufactured by Pfizer), up to 2mg/kg,
intravenous (bolus) or propofol (Diprivan 1% manufactured by
AstraZeneca), up to 2.5mg/kg, intravenous (bolus) as the
anaesthetic used for ECT. No restrictions were placed on the
psychiatric medications and or treatments prescribed either before
or during the course of the trial. The same applied for any rescue
medications. The standard ECT protocol set by the Royal Cornhill
Hospital and accredited by the Scottish Electroconvulsive
Accreditation Network was applied to all participants. Bilateral
ECT (bifrontotemporal position) was given twice per week. ECT
was administered using a brief pulse constant current apparatus
(Thymatron DGx). Any prescribed benzodiazepines were withheld
24 h before treatment so as to not interfere with ECT. On arrival at
the treatment room patients had baseline heart rate, non-invasive
blood pressure and oxygen saturation (SpO2) measured and the
left arm was isolated with a pressure cuff. An intravenous cannula
was inserted in the non-isolated arm. The patients in the ketamine
group were administered a hypnotic dose of ketamine of up to
2mg/kg followed by limb isolation and subsequent administration
of the muscle relaxant suxamethonium (0.5–1mg/kg). Those
in the propofol group were administered a hypnotic dose of
propofol up to 2.5mg/kg followed by limb isolation and
administration of suxamethonium (0.5–1mg/kg). Heart rate,
three-lead electrocardiogram (ECG), SpO2, fractional inspired
oxygen (FiO2), and end-tidal carbon dioxide (EtCO2) were
monitored continuously during the procedure. All participants
received positive pressure ventilation with 100% oxygen during
the procedure until spontaneous respiration resumed. Non-invasive
blood pressure was measured before the administration of the
anaesthetic, immediately post-seizure and repeated if necessary.
In the recovery room patients received oxygen-enriched air via
a facemask, while non-invasive blood pressure and SpO2 were
monitored.
Seizure threshold was defined as the minimum dose required
to produce a tonic–clonic seizure of 15 s or longer (measured by
electroencephalogram (EEG)). A titration method (starting at
50millicoulombs (mc), 100mc, 175mc, then increased by
50mc) was used to determine this seizure threshold and once
established the treating dose was given at twice the threshold.
No seizure or one less than 15 s increased dosage by 50mc.
Outcomes
The primary outcome was patients’ illness severity as assessed
using the 17-item Hamilton Rating Scale for Depression
(HRSD)21 and the Montgomery–A˚sberg Depression Rating Scale
(MADRS).22 Both are commonly used ratings scales. The MADRS
is recommended by the Scottish ECT Accreditation Network and
thus is used across Scotland. The secondary outcome, patients’
cognitive function, was also assessed before ECT using the
Cambridge Automated Neuropsychological Test Battery Spatial
Recognition Memory task (CANTAB SRM).23 Our research group
have found that the CANTAB SRM is sensitive to memory deficits
following ECT.24,25
Patients were assessed before the first ECT treatment (within
2–48 h), after the fourth treatment (within 24–48 h), at the end
of treatment (within 24–48 h) and 1 month after the end of
treatment by researchers masked to the anaesthetic employed.
The pre-ECT, post-fourth (ECT4) and post-final ECT assessments
were generally conducted in a quiet room in the hospital.
The 1-month post-ECT assessments were completed in a quiet
room in the hospital or the patient’s home. Each assessment took
approximately 35min. Patients, their treating medical teams and
all researchers making assessments were masked to the anaesthetic
allocation. Researchers conducting ratings were trained in the
administration of all measures.
Sample size
The sample size of 40 patients was based on a similarly sized
sample26 where a large measurable reduction in HRSD scores
was found after four ECT treatments following ketamine v.
propofol anaesthesia. KANECT ended when the sample size was
achieved.
Changes to methods after trial commencement
Several issues arose prior to completing the analysis that resulted
in a change to the original analysis plan published in the trial’s
protocol. First, for four patients who had four or fewer ECT
treatments the second assessment (post-ECT4) did not exist as
this was their post-final ECTassessment, meaning that either these
patients could not be included in an analysis using all four
assessments or the analyses could not examine all four assessments
for all patients. The trial protocol stated that the primary outcome
would be assessed by examining the change in depression ratings
over the course of treatment and after treatment. To this end, two
sets of analyses were employed. The first set employed analysis of
covariance (ANCOVA) to examine change over the acute stage of
2
Fernie et al
Ketamine as the anaesthetic for electroconvulsive therapy
treatment using all available data (n= 35) for the pre-ECT and
post-ECT4 assessments (including data from the four patients
who had four or fewer ECT treatments). The second set examined
change after treatment, comparing pre-ECT with post-final ECT
and the 1-month follow-up, and dropping the post-ECT4
assessment. Here, data from the four patients who had four or
fewer ECT treatments were included at the post-final ECT
assessment.
A second issue for the second analysis set was that loss to
follow-up meant that data were not available from all patients
at all points (see Missing data). This meant that employing
ANCOVAs to analyse change across time, as specified in the
trial protocol, was not appropriate because ANCOVAs delete
data list-wise, meaning any participant with missing data
would be excluded. This would result in an underpowered and
unrepresentative analysis. Instead, mixed models analyses were
employed. These analyses have a number of advantages over
ANCOVA in that they use all available data and handle missing
data appropriately. Mixed models also account for correlation
between repeated measurements on the same participant, and
allow for the addition of the covariates used in the stratification
randomisation procedure. Thus, mixed models can be thought
of as examining the same thing as ANCOVA but using all available
data. Our group have previously employed these analyses with
similar data.24,25
Statistical analyses
All analyses were computed in SPSS 22.0 and conducted by a
researcher masked to the group assignment (G.F.). An independent
samples t-test was used to analyse whether there was a difference
in the number of ECT treatments administered between groups.
Analyses were conducted for both depressive rating measures
(HRSD and MADRS) and changes in cognitive function
(CANTAB SRM performance). All analyses were run with
anaesthetic and time as fixed factors and anaesthetic6time as
an interaction term. Age and gender were included as covariates.
In an acute effects analysis, analysis of covariance (ANCOVA)
compared outcomes pre-ECTwith post-ECT4. Partial eta-squared
(Z2p) provided an estimate of effect size with 95% confidence
intervals listed with the ketamine group reported first; and in
interactions with time, the first reported confidence interval is
the earliest time point. In a treatment effects analysis, linear mixed
models compared outcomes assessed pre-ECT with those at
post-final ECT and 1-month assessments. In each mixed model
a compound symmetry covariance matrix27 was compared with
a first-order autoregressive and an unstructured covariance
matrix. Model fit was assessed using Akaike’s Information
Criterion (AIC) and the better fitting model (smallest AIC)
reported. In each case this was the model with the compound
symmetry covariance matrix. Estimation proceeded using
restricted maximum likelihood to a maximum of 100 iterations.
Residuals were examined following model fit for non-normality
using Q–Q plots. All models were normal.
Missing data
Data were analysed if patients completed any follow-up assessment
following pre-ECT assessment (n=35). Data remained in the
trial for analysis where appropriate despite subsequent loss to
follow-up. As shown in Fig. 1, additional data were missing
post-ECT4 for one patient who refused to complete the CANTAB
SRM. Post-final ECT, one patient was discharged home before an
assessment could be completed and a visit could not be scheduled
within 2 days. A second patient was discharged home but the
post-final ECT assessment was completed by telephone. CANTAB
SRM data are thus missing for this patient. As four patients had
four ECT treatments or fewer their data could be counted as
post-ECT4 or post-final ECT, but not included as both in the
same analysis. This necessitated two sets of analyses as elaborated
upon above.
Results
Recruitment
In total, 55 patients were screened eligible to participate in
KANECT. Of these, 52 were approached to participate and 40
consented, of whom 22 were female. As patients were randomly
assigned to receive ketamine or propofol stratified by gender
and age (465 and 465), baseline demographic characteristics
of each group were not statistically significant. Both groups con-
tained equal numbers of males (n=9) and females (n= 11). Mean
age was 51.76 (s.d. = 9.97) and 49.88 (s.d. = 12.53) in the ketamine
and propofol groups respectively. Baseline depression ratings and
CANTAB performance are displayed in Table 1.
Over the course of the study 14 patients were lost to follow-up
or withdrew. One patient withdrew before ECT was completed,
four were withdrawn either because of ECT being abandoned or
medical decisions to change the anaesthetic. One patient was
withdrawn from the trial following the end of ECT but before
any post-final ECT assessment because of their exposure to ‘legal
high’ substances. A further two patients withdrew from the trial
prior to the 1-month assessment, and three more did not respond
to attempts to arrange the 1-month assessment. One patient
returned for a further course of ECT, and two others were prescribed
maintenance ECT before the 1-month assessment. Fig. 1 shows these
withdrawals. The five patients (four from the ketamine group) who
withdrew or were withdrawn after commencement of ECT but be-
fore a follow-up assessment were significantly older, t(38)=72.11,
P50.05 (x =60.32) than those who continued (x =49.46) but there
was no significant difference in their HRSD (x =21.6 v. 25.91),
MADRS (x =31.0 v. 36.0) or CANTAB SRM (x =0.68 v. 0.72)
scores. Data from these patients were not examined further. The
number of ECT treatments received by patients in each group
(ketamine: x =7.88, s.d.= 3.18; propofol: x =7.26, s.d.= 2.23) was
compared using an independent samples t-test. No significant
difference was found, t(33)51.0, P40.05, d=0.23.
Acute effects analysis
(between pre-ECT and post-ECT4)
For the HRSD, the ANCOVA found no main effect of anaesthetic
(F(1,31) = 2.93, mean square error (MSE) = 25.10, P40.05,
Z2p = 0.09, ketamine: 95% CI 19.60–24.83, propofol: 95% CI
16.80–21.58), a main effect of time (F(1,31) = 12.77, MSE= 46.97,
P50.01, Z2p = 0.29, pre-ECT: 95% CI 23.29–28.60, post-ECT4:
95% CI 13.31–17.60) where pre-ECT scores were higher than
post-ECT4 scores, and no interaction between anaesthetic and
time (F(1,31)51.0, Z
2
p = 0.03, pre-ECT, ketamine: 95% CI 22.63–
30.63, propofol: 95% CI 21.60–28.91; post-ECT4, ketamine:
95% CI 14.57–21.04, propofol: 95% CI 10.16–16.07). No inter-
action was found between time and gender (F(1,31)51.0) but an
interaction between time and age group was found
(F(1,31) = 4.53, MSE= 46.97, P50.05). Examination of mean
scores showed that HRSD scores decreased over time for younger
adults (x = 26.50–14.91; n= 32) but not for older adults
(x = 19.33–19.0; n= 3). Removing the covariates, as advocated by
Gilmore28 and IBM,29 resulted in a larger main effect of time
(F(1,33) = 38.40, MSE= 50.58, P50.01).
The MADRS ANCOVA found no main effect of anaesthetic
(F(1,31) = 1.42, MSE= 50.73, P40.05, Z
2
p = 0.04, ketamine: 95%
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CI 26.44–33.87, propofol: 95% CI 23.76–30.54), a main effect of
time (F(1,31) = 10.40, MSE= 76.12, P50.01, Z
2
p = 0.25, pre-ECT:
95% CI 33.12–38.87, post-ECT4: 95% CI 17.71–24.93) with pre-
ECT scores higher than post-ECT4 scores, and no interaction
between anaesthetic and time (F(1,31) = 2.05, P40.05, Z
2
p = 0.06,
pre-ECT, ketamine: 95% CI 31.60–40.26, propofol: 95% CI
32.10–40.02; post-ECT4, ketamine: 95% CI 18.95–29.82, propofol:
95% CI 13.29–23.23). There were no interactions between time
and gender (F(1,31)51.0) or time and age (F(1,31) = 2.08,
Ps40.05). Removing the covariates again resulted in a larger
within-participants effect of time (F(1,33) = 48.78, MSE= 77.53).
The ANCOVA examining mean CANTAB SRM proportion
correct from all patients for whom there was data pre-ECT and
post-ECT4 (n= 34) found no main effects of anaesthetic
(F(1,30)51.0, MSE=0.01, Z
2
p = 0.03, ketamine: 95% CI 0.61–0.70,
propofol: 95% CI 0.64–0.72) or time (F(1,30)51.0, MSE50.02,
Z2p = 0.02, pre-ECT: 95% CI 0.68–0.77, post-ECT4: 95% CI 0.57–
0.65), nor was there an interaction between anaesthetic and time
(F(1,30)51.0, Z
2
p50.01, pre-ECT, ketamine: 95% CI 0.65–0.78,
propofol: 95% CI 0.67–0.80; post-ECT4, ketamine: 95% CI 0.54–
0.66, propofol: 95% CI 0.57–0.68). There were no interactions
between time and gender or time and age (both Fs(1,30)51.0).
Removing the covariates resulted in a significant within-participants
effect of time (F(1,32) = 14.54, MSE50.02, P50.01): post-ECT4
scores were lower.
Treatment effects analysis (between pre-ECT,
post-final ECT and 1-month post-ECT)
Linear mixed models examined group differences in depressive
symptoms or cognitive function over time (pre-ECT, post-final
ECT and at the 1-month follow-up). These data are displayed in
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Allocated to ketamine (n=20)
. Received allocated intervention (n=20)
. Did not receive allocated intervention (n=0)
Lost to follow-up (n=7)
– Discontinued intervention (n=4)
. withdrew consent (n=1)
. withdrawn because of high blood pressure (n=1)
. withdrawn following anaesthetist’s review of
ventillatory capacity (n=1)
. withdrawn because of anaesthetic change (n=1)
– Follow-up assessment missed (n=3)
. Returned for maintenance ECT (n=1)
. Withdrew before or did not attend 1 month
assessment (n=2)
. [54 ECT treatments (n=2)]
Analysed (n=16)
. Excluded from analysis (n=4)
. Completed post-ECT4 assessment (n=14)
. Completed post-final ECT assessment (n=16)
. Completed 1-month assessment (n=13)
Allocated to propofol (n=20)
. Received allocated intervention (n=20)
. Did not receive allocated intervention (n=0)
Lost to follow-up (n=7)
– Discontinued intervention (n=1)
. ECT abandoned
– Follow-up assessment missed
. Returned for maintenance ECT prior to
1-month assessment (n=1)
. Returned for another ECT course prior to
1-month assessment (n=1)*
. Discharged home before post-final ECT
assessment (n=1)
. Withdrawn prior to post-final ECT assessment
because of exposure to legal high (n=1)
. Withdrew before or did not attend 1-month
assessment (n=3)
. [54 ECT treatments (n=2)]*
Analysed (n=19)
. Excluded from analysis (n=1)
. Completed post-ECT4 assessment (n=17){
. Completed post-final ECT assessment (n=17){,{
. Completed 1-month assessment (n=13)
Assessed for eligibility (n=55)
Randomised (n=40)
Allocation
Follow-up
Analysis
Excluded (n=15)
. Not meeting inclusion criteria (n=3)
. Declined to participate (n=12)
. Other reasons (n=0)
Enrolment
6
6
6
6
6
6
6
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Fig. 1 CONSORT flow diagram showing patient eligibility and inclusion in the trial.
*One patient is the same patient; {Patient refused Cambridge Automated Neuropsychological Test Battery Spatial Recognition Memory task (CANTAB SRM) (n=1); {Completed over
telephone so no CANTAB (n=1). ECT, electroconvulsive therapy.
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Fig. 2. For HRSD ratings, there was no significant effect of
anaesthetic (F(1) = 2.54, P40.05) but a significant effect of time
was found (F(2) = 46.92, P50.01). Across patients HRSD scores
were reduced following ECT. The interaction between factors
was not significant (F(2)51.0, P40.05). For MADRS ratings,
there was also no significant effect of anaesthetic (F(1) = 1.45,
P40.05) and a significant effect of time (F(2) = 55.03, P50.01).
Across patients MADRS scores were reduced following ECT. The
interaction between factors was not significant (F(2) = 2.92,
P= 0.06) but Fig. 2(b) shows this almost significant interaction
is because of the steeper reduction in MADRS scores post-final
ECT in the propofol group. On the CANTAB SRM, there was
no significant effect of anaesthetic (F(1)51.0, P40.05) but a
significant effect of time was found (F(2) = 5.84, P50.01). Pairwise
comparisons revealed that post-final ECT CANTAB SRM
proportion correct was lower than the pre-ECT baseline. The
interaction between factors was not significant (F(2)51.0, P40.05).
Harms
One serious adverse event (prolonged hospital admission) was
recorded in the propofol group when a participant developed an
elevated mood following their ECT course. No adverse events
related to exposure to ketamine occurred. It is also worth noting
anecdotally that the psychotomimetic effects of ketamine were
absent in our sample.
Discussion
Main findings and comparison with findings from
other studies
Contrary to our hypotheses, when ketamine was used as the
anaesthetic for ECT there was no significant difference in the
number of ECT treatments, ratings of depression severity or
cognitive function when compared with propofol. Indeed,
although patients in both groups improved with treatment,
examination of mean depression ratings on both measures
actually show higher, albeit not significantly different, scores in
the ketamine group.
These results join recent evidence7 that suggests ketamine’s
antidepressant effect does not emerge when it is used as the
anaesthetic in ECT, despite promising prospects in other contexts
on an acute timescale (for example Zarate et al,3 Berman et al,5
and Kudoh et al 30). Yoosefi et al 31 have recently reported a
randomised, double-blind clinical trial comparing ketamine and
thiopental as the anaesthetics for ECT. Patients in both groups
received six ECT treatments (by design). Although patients who
were administered ketamine had lower scores on the HRSD
following the first ECT and before the second, there was no
between-group difference in depression ratings at the end of
treatment or 1 month after. Similarly, Rasmussen et al 32 compared
ketamine with methohexital but did not find any significant
differences in depression ratings between the two anaesthetics.
Consistently, when ketamine is used in addition to thiopentone
anaesthetic no differences in depressive symptoms after the initial
and sixth ECT,33 nor at the end of treatment,34 have been found.
The KANECT study found no significant difference between
ketamine and propofol on a cognitive measure previously shown
to detect post-ECT impairments. Again, other recent studies
support this finding. Loo et al 34 reported no difference in a large
number of neuropsychological outcomes, whereas Rasmussen
et al 32 and Yoosefi et al 31 report conflicting results with the
Mini-Mental State Examination (MMSE).35 Rasmussen et al
found no differences whereas Yoosefi et al found an improvement
1 month after the final ECT only in the ketamine group. These
differences may reflect the insensitivity of the MMSE to specific
cognitive deficits, and its susceptibility to changes based on patient
orientation.
This trial was adequately powered to detect a difference
between anaesthetic groups should it have occurred. The sample
size (n= 40) was based on Okamoto et al 26 where a large group
difference in symptom reduction after the fourth treatment was
found. They found a large effect based on an average 24-point
drop in HRSD scores in the ketamine group (n= 8) v. a 14-point
drop in the propofol group (n=1). KANECT’s power calculation
was based on these results determining that given a large effect size
20 patients per group would be needed (two-tailed, power of 90%,
critical t of 2.02). We achieved the same sample size as Okamoto
et al26 but the drop in mean HRSD scores was equivalent between
groups (ketamine 9.94, propofol 11.21). The equivalent critical
t-value was also smaller: 1.71 (F(1,31) = 2.93, where t=
ﬃp
F).
Crucially, there were methodological and statistical improvements
in KANECT that may explain this difference. Okamoto et al
randomised on the basis of patient preference and used repeated
t-tests to compare scores after each ECT. In KANECT, patients
and raters were masked to anaesthetic allocation, randomisation
was minimised by gender and age (decreasing the degrees of
freedom), and type-I error inflation was controlled appropriately.
For these reasons, it is doubtful that a group difference would have
been found should a larger sample been recruited.
Okamoto et al26 kept the number of ECTs constant between
groups. This was a dependent variable in the current trial and
fewer ECTs were administered in both groups although the
numbers were broadly equivalent (8 in Okamoto et al v. 7.88
and 7.26 for ketamine and propofol, respectively here). This trial
found no difference in the number of ECT treatments between
anaesthetic groups and although this mirrored the depression
ratings results, one potential source of bias for this measure was
that the number of treatments was determined by the prescribing
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Table 1 Means scores on each dependent measure by group (standard deviation).
Mean (s.d.)
Pre-ECT Post-ECT4 Post-final ECT 1 month post-ECT
Hamilton Rating Scale for Depression
Ketamine 27.19 (6.47) 17.25 (6.88) 13.50 (9.32) 14.08 (8.08)
Propofol 24.79 (8.50) 13.58 (5.71) 8.41 (4.70) 12.08 (9.86)
Montgomery–A˚sberg Depression Rating Scale
Ketamine 36.38 (8.29) 23.81 (11.20) 18.69 (16.48) 17.85 (13.15)
Propofol 35.68 (8.39) 18.74 (9.44) 8.18 (6.27) 17.15 (13.75)
Cambridge Automated Neuropsychological Test Battery Spatial Recognition
Memory task
Ketamine 0.71 (0.11) 0.60 (0.12) 0.60 (0.16) 0.70 (0.11)
Propofol 0.72 (0.15) 0.63 (0.10) 0.64 (0.11) 0.65 (0.12)
ECT, electroconvulsive therapy.
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clinician rather than the study protocol. Although there is no
reason to doubt that depression severity was the primary reason
to continue ECT, and the prescribing clinician was masked to
anaesthetic allocation, it is possible that other unknown factors
had an influence.
Although no evidence of an enhanced antidepressive effect of
ketamine was found, it was well-tolerated for ECT. No adverse
events related to exposure to ketamine occurred. It is also worth
noting anecdotally that the psychotomimetic effects of ketamine
were absent in our participants. However, Caddy et al 8 reported
that ketamine caused more confusion and emotional blunting
compared with placebo, with the former conclusion also reached
by McGirr et al.7
Limitations
Our results are limited by a number of factors. First, because of
patient attrition we were unable to compare treatment effects at
all follow-ups for our entire sample meaning the analysis lost
some power. Our use of linear mixed models goes some way to
mitigate this limitation as such models use all available data and
appropriately account for within-participant correlations in
measurements. Second, although three of the four patients whose
participation was discontinued for medical reasons were in the
ketamine group, these withdrawals were made for medical reasons
rather than as a result of anaesthetic assignment. Third, a feature
of our trial design was that the decision on management of the
ECT course was taken by the patients’ treating clinicians, who
were masked to anaesthetic assignment. Therefore, treatment
failures (new ECT course or maintenance ECT prior to 1-month
follow-up, n=3) were outside our control and we are confident
are independent of anaesthetic assignment. Fourth, we placed
no restrictions on concomitant medication prescribing during
the course of the trial except that benzodiazepines were withdrawn
prior to ECT. Although it is plausible that other medication may
have affected our results, randomisation means that these should
be similarly distributed between our groups.
In conclusion, the results of this double-blind, parallel-design,
RCT demonstrate that ketamine as an anaesthetic for ECT does
not enhance the efficacy of ECT. Although patients in both groups
improved with treatment, neither of the primary outcomes of the
number of ECT treatments received nor the change in depression
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Fig. 2 Mean scores on the dependent measures across time (pre-electroconvulsive therapy (ECT), post-final ECT and 1-month post-ECT)
by anaesthetic group (treatment effects analysis).
(a) Group differences in Hamilton Rating Scale for Depression (HRSD) ratings across follow-up, (b) group differences in Montgomery–A˚sberg Depression Rating Scale (MADRS) ratings
across follow-up, (c) group differences in Cambridge Automated Neuropsychological Test Battery Spatial Recognition Memory task (CANTAB SRM) scores across follow-up. Error bars
are the standard error of the mean.
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symptom severity showed any differences between anaesthetics.
Nor was a difference found in the degree of impairment on the
cognitive measure we employed.
Gordon Fernie, PhD, Centre for Healthcare Randomised Trials (CHaRT), Health
Services Research Unit, University of Aberdeen. Aberdeen, UK; James Currie,
MBChB, BSc, Jennifer S. Perrin, PhD, NHS Grampian, Royal Cornhill Hospital,
Aberdeen, UK; Caroline A. Stewart, BSc, PhD, Division of Neuroscience, University
of Dundee, Dundee, UK; Virginica Anderson, MD, FRCA, NHS Grampian, Royal
Cornhill Hospital, Aberdeen, UK; Daniel M. Bennett, MBChB, MRCPsych, MD,
MMED, Division of Applied Medicine (Psychiatry), University of Aberdeen, Aberdeen
and NHS Grampian, Royal Cornhill Hospital, Aberdeen, UK; Steven Hay, MBChB,
MRCPsych, NHS Grampian, Royal Cornhill Hospital, Aberdeen, UK; Ian C. Reid
(deceased), PhD, MRCPsych, previously at Division of Applied Medicine (Psychiatry),
University of Aberdeen, Aberdeen and NHS Grampian, Royal Cornhill Hospital,
Aberdeen, UK
Correspondence: Gordon Fernie, Centre for Healthcare Randomised Trials
(CHaRT), Health Services Research Unit, 3rd Floor Health Services Building,
Fosterhill, University of Aberdeen, Aberdeen AB25 2ZD, UK. Email:
g.fernie@abdn.ac.uk
First received 10 Jun 2016, final revision 18 Oct 2016, accepted 18 Nov 2016
Funding
The Chief Scientists Office (CSO) of Scotland funded this research.
Acknowledgements
The trial protocol is available for download here: http://www.abdn.ac.uk/ims/research/
neuroscience/mood-disorders.php. This manuscript reports the results of the final clinical
trial led by I.C.R. at the University of Aberdeen. Despite his untimely death in 2014, this
work represents the culmination of his academic interest in the use and mechanisms of
action underlying electroconvulsive therapy (ECT), which started with preclinical research
published back in 1993. I.C.R. was always a champion of rigorous research into the causes
of and treatments for mental illness and his influence in the field will be sorely missed. Our
thanks go to all the patients who participated in the trial; Alison Campbell for pre-ECT
patient assessment, recruitment, anaesthetic management during the trial and assistance
in data collection; Ellen Robertson and Kate Ferries for their help in patient care and data
collection; Jennifer Adams for her help with data collection, and to members of the
independent Trial Steering Committee: Keith Matthews, Ian Anderson, John Norrie and
Darren Gibson.
References
1 World Health Organization. Depression Fact sheet N369. WHO, 2015
(http://www.who.int/mediacentre/factsheets/fs369/en/).
2 Waite J, Easton A. The ECT Handbook (3rd edn). Royal College of
Psychiatrists, 2013.
3 Zarate Jr CA, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA,
et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-
resistant major depression. Arch Gen Psychiatry 2006; 63: 856–64.
4 Murrough JW, Iosifescu DV, Chang LC, Al Jurdi RK, Green CE, Perez AM, et al.
Antidepressant efficacy of ketamine in treatment-resistant major depression:
a two-site randomized controlled trial. Am J Psychiatry 2013; 170: 1134–42.
5 Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, et al.
Antidepressant effects of ketamine in depressed patients. Biol Psychiatry
2000; 47: 351–4.
6 McGirr A, Berlim MT, Bond DJ, Fleck MP, Yatham LN, Lam RW. A systematic
review and meta-analysis of randomized, double-blind, placebo-controlled
trials of ketamine in the rapid treatment of major depressive episodes.
Psychol Med 2015; 45: 693–704.
7 McGirr A, Berlim MT, Bond DJ, Neufeld NH, Chan PY, Yatham LN, et al.
A systematic review and meta-analysis of randomized controlled trials of
adjunctive ketamine in electroconvulsive therapy: efficacy and tolerability.
J Psychiatr Res 2015; 62: 23–30.
8 Caddy C, Amit BH, McCloud TL, Rendell JM, Furukawa TA, McShane R, et al.
Ketamine and other glutamate receptor modulators for depression in adults.
Cochrane Database Syst Rev 2015; 9: CD011611.
9 Fond G, Loundou A, Rabu C, Macgregor A, Lanc¸on C, Brittner M, et al.
Ketamine administration in depressive disorders: a systematic review and
meta-analysis. Psychopharmacology 2014; 231: 3663–76.
10 Coyle CM, Laws KR. The use of ketamine as an antidepressant: a systematic
review and meta-analysis. Hum Psychopharmacol 2015; 30: 152–63.
11 Lee EE, Della Selva MP, Liu A, Himelhoch S. Ketamine as a novel treatment
for major depressive disorder and bipolar depression: A systematic review
and quantitative meta-analysis. Gen Hosp Psychiatry 2015; 37: 178–84.
12 Brakemeier E, Berman R, Prudic J, Zwillenberg K, Sackeim HA. Self-evaluation
of the cognitive effects of electroconvulsive therapy. J ECT 2011; 27: 59–66.
13 Robertson H, Pryor R. Memory and cognitive effects of ECT: informing and
assessing patients. Adv Psychiatr Treat 2006; 12: 228–37.
14 Collingridge GL, Kehl SJ, McLennan H. Excitatory amino acids in synaptic
transmission in the Schaffer collateral-commissural pathway of the rat
hippocampus. J Physiol 1983; 334: 33–46.
15 Morris RGM, Anderson E, Lynch GS, Baudry M. Selective impairment of
learning and blockade of long-term potentiation by an N-methyl-D-aspartate
receptor antagonist, AP5. Nature 1986; 319: 774–6.
16 Stewart CA, Reid IC. Ketamine prevents ECS-induced synaptic enhancement
in rat hippocampus. Neurosci Lett 1994; 178: 11–4.
17 Krystal AD, Weiner RD, Dean MD, Lindahl VH, Tramontozzi III LA, Falcone G,
et al. Comparison of seizure duration, ictal EEG, and cognitive effects of
ketamine and methohexital anesthesia with ECT. J Neuropsychiatry Clin
Neurosci 2003; 15: 27–34.
18 McDaniel WW, Sahota AK, Vyas BV, Laguerta N, Hategan L, Oswald J.
Ketamine appears associated with better word recall than etomidate after a
course of 6 electroconvulsive therapies. J ECT 2006; 22: 103–6.
19 Scottish ECT Accreditation Network. Scottish ECT Accreditation Network
Annual Report 2015: A Summary of ECT in Scotland for 2014. ISD Scotland
Publications, 2015.
20 Taves DR. Minimization: a new method of assigning patients to treatment
and control groups. Clin Pharmacol Ther 1974; 15: 443–53.
21 Williams JBW, Kobak KA, Beck P, Engelhardt N, Lipsitz J, Olin J, et al.
The GRID-HAMD: standardisation of the Hamilton depression rating scale.
Int Clin Psychopharmacol 2008; 23: 120–9.
22 Montgomery SA, A˚sberg M. A new depression scale designed to be sensitive
to change. Br J Psychiatry 1979; 134: 382–9.
23 Owen AM, Sahakian BJ, Semple J, Polkey CE, Robbins TW. Visuo-spatial
short-term recognition memory and learning after temporal lobe excisions,
frontal lobe excisions or amygdalo-hippocampectomy in man.
Neuropsychologia 1995; 33: 1–24.
24 Fernie G, Bennett DM, Currie J, Perrin JS, Reid IC. Detecting objective and
subjective cognitive effects of electroconvulsive therapy: intensity, duration
and test utility in a large clinical sample. Psychol Med 2014; 44: 2985–94.
25 Falconer DW, Cleland J, Fielding S, Reid IC. Using the Cambridge
neuropsychological test automated battery (CANTAB) to assess the cognitive
impact of electroconvulsive therapy on visual and visuospatial memory.
Psychol Med 2010; 40: 1017–25.
26 Okamoto N, Nakai T, Sakamoto K, Nagafusa Y, Higuchi T, Nishikawa T. Rapid
antidepressant effect of ketamine anesthesia during electroconvulsive
therapy of treatment-resistant depression: comparing ketamine and propofol
anesthesia. J ECT 2010; 26: 223–7.
27 IBM. Problem Subject: Repeated Measures with Constant Covariates
in GLM. SPSS Knowledgebase Resolution Number 22133. IBM, 2010
(http://www-01.ibm.com/support/docview.wss?uid= swg21477023).
28 Gilmore GC. Inappropriate use of covariate analysis renders meaningless
results. J Int Neuropsychol Soc 2007; 13: 370.
29 IBM. Repeated Measures ANCOVA with a Constant Covariate in MIXED in
SPSS. SPSS Knowledgebase Resolution Number 22273. IBM, 2010 (http://
www-01.ibm.com/support/docview.wss?uid = swg21477006).
30 Kudoh A, Takahira Y, Katagai H, Takazawa T. Small-dose ketamine improves
the postoperative state of depressed patients. Anesth Analg 2002; 95: 114–8.
31 Yoosefi A, Sepehri AS, Kargar M, Akhondzadeh S, Sadeghi M, Rafei A, et al.
Comparing effects of ketamine and thiopental administration during
electroconvulsive therapy in patients with major depressive disorder:
a randomized, double-blind study. J ECT 2014; 30: 15–21.
32 Rasmussen KG, Kung S, Lapid MI, Oesterle TS, Geske JR, Nuttall GA, et al.
A randomized comparison of ketamine versus methohexital anesthesia in
electroconvulsive therapy. Psychiatry Res 2014; 215: 362–5.
33 Abdallah CG, Fasula M, Kelmendi B, Sanacora G, Ostroff R. Rapid
antidepressant effect of ketamine in the electroconvulsive therapy setting.
J ECT 2012; 28: 157–61.
34 Loo CK, Katalinic N, Garfield JBB, Sainsbury K, Hadzi-Pavlovic D, Mac-Pherson
R. Neuropsychological and mood effects of ketamine in electroconvulsive
therapy: a randomised controlled trial. J Affective Disord 2012; 142: 233–40.
35 Folstein MF, Folstein SE, McHugh PR. ‘‘Mini-mental state’’. A practical
method for grading the cognitive state of patients for the clinician. J Psychiatr
Res 1975; 12: 189–98.
7
CONSORT 2010 checklist  Page 1 
 
Data supplement to Fernie et al. Ketamine as the anaesthetic for electroconvulsive 
therapy: randomised controlled trial. Br J Psychiatry doi: 10.1192/bjp.bp.116.189134
CONSORT 2010 checklist  Page 2 
 Online Supplement DS1 
CONSORT 2010 checklist of information to include when reporting a randomised trial* 
 
Section/Topic 
Item 
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on page No 
Title and abstract 
 1a Identification as a randomised trial in the title 1 
1b Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts) 1 
Introduction 
Background and 
objectives 
2a Scientific background and explanation of rationale 1 
2b Specific objectives or hypotheses 1 
Methods 
Trial design 3a Description of trial design (such as parallel, factorial) including allocation ratio 1 
3b Important changes to methods after trial commencement (such as eligibility criteria), with reasons 2-3 
Participants 4a Eligibility criteria for participants 2 
4b Settings and locations where the data were collected 2 
Interventions 5 The interventions for each group with sufficient details to allow replication, including how and when they were 
actually administered 
2 
Outcomes 6a Completely defined pre-specified primary and secondary outcome measures, including how and when they 
were assessed 
2 
6b Any changes to trial outcomes after the trial commenced, with reasons N/A 
Sample size 7a How sample size was determined 2 
7b When applicable, explanation of any interim analyses and stopping guidelines N/A 
Randomisation:    
 Sequence 
generation 
8a Method used to generate the random allocation sequence 1-2 
8b Type of randomisation; details of any restriction (such as blocking and block size) 1-2 
 Allocation 
concealment 
mechanism 
9 Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), 
describing any steps taken to conceal the sequence until interventions were assigned 
1-2 
 
 Implementation 10 Who generated the random allocation sequence, who enrolled participants, and who assigned participants to 
interventions 
2 
CONSORT 2010 checklist  Page 3 
Blinding 11a If done, who was blinded after assignment to interventions (for example, participants, care providers, those 
assessing outcomes) and how 
2, 3 
11b If relevant, description of the similarity of interventions N/A 
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Figure 1 
13b For each group, losses and exclusions after randomisation, together with reasons Figure 1, 3 
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Baseline data 15 A table showing baseline demographic and clinical characteristics for each group 2, 3, Table 1 
Numbers analysed 16 For each group, number of participants (denominator) included in each analysis and whether the analysis was 
by original assigned groups 
Figure 1, 3 
Outcomes and 
estimation 
17a For each primary and secondary outcome, results for each group, and the estimated effect size and its 
precision (such as 95% confidence interval) 
3-4 
Calculated for 
ANCOVAs, 
but not mixed 
models. 
17b For binary outcomes, presentation of both absolute and relative effect sizes is recommended N/A 
Ancillary analyses 18 Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing 
pre-specified from exploratory 
N/A 
Harms 19 All important harms or unintended effects in each group (for specific guidance see CONSORT for harms) 5 
Discussion 
Limitations 20 Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses 6 
Generalisability 21 Generalisability (external validity, applicability) of the trial findings 5-6 
Interpretation 22 Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence 5-6 
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Registration 23 Registration number and name of trial registry 7 
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Funding 25 Sources of funding and other support (such as supply of drugs), role of funders 2: 
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